ArticleProstate cancer and prostatic diseases2017
The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer.
Article in Prostate cancer and prostatic diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Efficacy and safety of neoadjuvant therapies for high-risk and locally advanced prostate cancer in older adults: a systematic review and network meta-analysis.Frontiers in oncology · 2026Pooled it
- The Impact of Neoadjuvant Hormone Therapy on Surgical and Oncological Outcomes for Patients With Prostate Cancer Before Radical Prostatectomy: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2020Pooled it
- Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis.Asian journal of andrologyPooled it
- Recovery of urinary continence after neoadjuvant hormonal therapy plus radical prostatectomy: A multicenter retro-prospective cohort study with propensity score matching.Asian journal of urology · 2026Article
- Efficacy of neoadjuvant hormonal therapy combined with robot-assisted radical prostatectomy for oligometastatic prostate cancer: a multicenter retrospective study.Frontiers in oncology · 2026Article
- Efficacy of neoadjuvant novel hormonal therapy combined with radical prostatectomy for high-risk prostate cancer and analysis of biochemical recurrence-free survival.American journal of translational research · 2026Article
- Intraductal Carcinoma Predicts Poor Response to Neoadjuvant Therapy in High-risk Prostate Cancer: A Retrospective Analysis of a Prospective Trial.European urology open science · 2025Article
- Prognostic value of pathological sensitivity for high-risk, localized prostate cancer receiving neoadjuvant hormonal therapy combined with radical prostatectomy.Annals of medicine · 2025Article
- Nomogram for predicting the biochemical recurrence of prostate cancer after neoadjuvant androgen deprivation therapy.International urology and nephrology · 2023Article
- Effect of Neoadjuvant Hormonal Therapy on the Postoperative Course for Patients Undergoing Robot-Assisted Radical Prostatectomy.Journal of clinical medicine · 2023Article
- Comparison of neoadjuvant chemohormonal therapy vs. extended pelvic lymph-node dissection in high-risk prostate cancer treated with robot-assisted radical prostatectomy.Scientific reports · 2023Article
- Clinical Analysis of Perioperative Outcomes on Neoadjuvant Hormone Therapy before Laparoscopic and Robot-Assisted Surgery for Localized High-Risk Prostate Cancer in a Chinese Cohort.Current oncology (Toronto, Ont.) · 2022Article
- Multimodal therapy including robot-assisted radical cystoprostatectomy for locally advanced prostate cancer with bladder and ureteral invasion: A case report.IJU case reports · 2022Article
- Review
- Cyproterone acetate acts as a disruptor of the aryl hydrocarbon receptor.Scientific reports · 2021Article
- Neoadjuvant Androgen Deprivation Therapy Effects on Perioperative Outcomes Prior to Radical Prostatectomy: Eleven Years of Experiences at Ramathibodi Hospital.Research and reports in urology · 2021Article
- Article
- Cost-effectiveness comparison between neoadjuvant chemohormonal therapy and extended pelvic lymph node dissection in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis.Medical oncology (Northwood, London, England) · 2017Article
- Clinical efficacy of neoadjuvant chemohormonal therapy combined with laparoscopic radical prostatectomy in high-risk Prostate Cancer.Pakistan journal of medical sciencesArticle
- Neoadjuvant Therapy in High-Risk Prostate Cancer.Indian journal of urology : IJU : journal of the Urological Society of IndiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 16 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral randomized controlled trials assessed the outcomes of patients treated with neoadjuvant hormonal therapy (NHT) before radical prostatectomy (RP). The majority of them included mainly low and intermediate risk prostate cancer (PCa) without specifically assessing PCa-related death (PCRD). Thus, there is a lack of knowledge regarding a possible effect of NHT on PCRD in the high-risk PCa population. We aimed to analyze the effect of NHT on PCRD in a multicenter high-risk PCa population treated with RP, using a propensity-score adjustment.
methodsThis is a retrospective multi-institutional study including patients with high-risk PCa defined as: clinical stage T3-4, PSA >20 ng ml
resultsAfter application of the inclusion/exclusion criteria, 1573 patients remained for analysis; 1170 patients received RP and 403 NHT+RP. Median follow-up was 56 months (interquartile range 29-88). Eighty-six patients died of PCa and 106 of other causes. NHT decreased the risk of PCRD (hazard ratio (HR) 0.5; 95% confidence interval (CI) 0.32-0.80; P=0.0014). An interaction effect between NHT and radiotherapy (RT) was observed (HR 0.3; 95% CI 0.21-0.43; P<0.0008). More specifically, of patients who received adjuvant RT, those who underwent NHT+RP had decreased PCRD rates (2.3% at 5 year) compared to RP (7.5% at 5 year). The retrospective design and lack of specific information about NHT are possible limitations.
conclusionsIn this propensity-score adjusted analysis from a large high-risk PCa population, NHT before surgery significantly decreased PCRD. This effect appeared to be mainly driven by the early addition of RT post-surgery. The specific sequence of NHT+RP and adjuvant RT merits further study in the high-risk PCa population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.